WG
SPRY icon

Winton Group’s ARS Pharmaceuticals SPRY Stock Holding History

Winton Group’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$264K Buy
+32,900
New +$283K 0.01% 930

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tyro Capital Management Miami, Florida $446M AUM 84.15% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Winton Group's SPRY Position: Q2 2026 in Review

Winton Group opened a new position in ARS Pharmaceuticals (SPRY) in Q2 2026: 32,900 shares worth $264K. The stake represents 0.01% of the portfolio and ranks #930 among its holdings.

206 funds tracked by Wall St. Rank hold SPRY as of Q2 2026.

  • Winton Group held 32,900 shares of ARS Pharmaceuticals worth $264K as of Q2 2026.
  • ARS Pharmaceuticals was a new Winton Group position in Q2 2026.
  • ARS Pharmaceuticals made up 0.01% of Winton Group's portfolio in Q2 2026, its #930 holding.
  • 206 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.